Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson's disease.
Company Details
- Founded
- -
- Address
- London Wc1r
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://axovant.com
- Keywords
- Medmenham.
- HQ
- London Wc1r
Axovant Sciences Ltd Questions
Axovant Sciences Ltd's website is http://axovant.com
Axovant Sciences Ltd's LinkedIn profile is https://uk.linkedin.com/company/axovant-sciences-ltd
Axovant Sciences Ltd's industry is
Pharmaceutical Manufacturing
Axovant Sciences Ltd's top competitors are
Cahootz,
Tcat At Snbts,
Yap Therapeutics, Inc.,
Shott Trinova,
Triveritas Ltd,
Synpromics Ltd,
Voyager Therapeutics, Inc.,
Chromatin Bioscience,
Axovant Sciences, Inc.,
Amazentis.
Axovant Sciences Ltd's categories are Pharmaceutical Manufacturing
Axovant Sciences Ltd's founding year is 2014
